174 related articles for article (PubMed ID: 20523097)
1. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib.
Bozas G; Roy A; Ramasamy V; Maraveyas A
Onkologie; 2010; 33(6):321-3. PubMed ID: 20523097
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases.
Hoefert S; Eufinger H
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Oct; 110(4):463-9. PubMed ID: 20692189
[TBL] [Abstract][Full Text] [Related]
3. [Sunitinib and zoledronic acid induced osteonecrosis of the jaw].
Soós B; Vajta L; Szalma J
Orv Hetil; 2015 Nov; 156(46):1865-70. PubMed ID: 26548471
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports.
Agrillo A; Nastro Siniscalchi E; Facchini A; Filiaci F; Ungari C
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):952-7. PubMed ID: 22953645
[TBL] [Abstract][Full Text] [Related]
5. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature.
Fusco V; Porta C; Saia G; Paglino C; Bettini G; Scoletta M; Bonacina R; Vescovi P; Merigo E; Lo Re G; Guglielmini P; Di Fede O; Campisi G; Bedogni A
Clin Genitourin Cancer; 2015 Aug; 13(4):287-294. PubMed ID: 25586958
[TBL] [Abstract][Full Text] [Related]
7. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications.
Nicolatou-Galitis O; Migkou M; Psyrri A; Bamias A; Pectasides D; Economopoulos T; Raber-Durlacher JE; Dimitriadis G; Dimopoulos MA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Feb; 113(2):234-8. PubMed ID: 22669112
[TBL] [Abstract][Full Text] [Related]
8. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Beuselinck B; Wolter P; Karadimou A; Elaidi R; Dumez H; Rogiers A; Van Cann T; Willems L; Body JJ; Berkers J; Van Poppel H; Lerut E; Debruyne P; Paridaens R; Schöffski P
Br J Cancer; 2012 Nov; 107(10):1665-71. PubMed ID: 23132391
[TBL] [Abstract][Full Text] [Related]
9. Osteonecrosis of the jaw related to sunitinib.
Koch FP; Walter C; Hansen T; Jäger E; Wagner W
Oral Maxillofac Surg; 2011 Mar; 15(1):63-6. PubMed ID: 20401503
[TBL] [Abstract][Full Text] [Related]
10. Avascular osteonecrosis of the mandible following bisphosphonate therapy.
Chandra PA; Chandra AB; Todd GK
Am J Ther; 2009; 16(1):65-7. PubMed ID: 22573056
[TBL] [Abstract][Full Text] [Related]
11. Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma.
Brunello A; Saia G; Bedogni A; Scaglione D; Basso U
Bone; 2009 Jan; 44(1):173-5. PubMed ID: 18849018
[TBL] [Abstract][Full Text] [Related]
12. Case 2. Osteonecrosis of the jaws associated with bisphosphonate therapy.
Mignogna MD; Fedele S; Lo Russo L; Ciccarelli R; Lo Muzio L
J Clin Oncol; 2006 Mar; 24(9):1475-7. PubMed ID: 16549843
[No Abstract] [Full Text] [Related]
13. Sunitinib related osteonecrosis of jaw: a case report.
Fleissig Y; Regev E; Lehman H
Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Mar; 113(3):e1-3. PubMed ID: 22676833
[TBL] [Abstract][Full Text] [Related]
14. [Osteonecrosis of the jaw developing during bisphosphonate treatment].
Udvardy E; Redl P; Márton I
Magy Onkol; 2008 Mar; 52(1):81-7. PubMed ID: 18403302
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile?
Ayllon J; Launay-Vacher V; Medioni J; Cros C; Spano JP; Oudard S
Ann Oncol; 2009 Mar; 20(3):600-1. PubMed ID: 19188135
[No Abstract] [Full Text] [Related]
16. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy.
Estilo CL; Van Poznak CH; Wiliams T; Bohle GC; Lwin PT; Zhou Q; Riedel ER; Carlson DL; Schoder H; Farooki A; Fornier M; Halpern JL; Tunick SJ; Huryn JM
Oncologist; 2008 Aug; 13(8):911-20. PubMed ID: 18695259
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
Haidar A; Jønler M; Folkmar TB; Lund L
Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Fitzpatrick SG; Stavropoulos MF; Bowers LM; Neuman AN; Hinkson DW; Green JG; Bhattacharyya I; Cohen DM
J Oral Maxillofac Surg; 2012 Feb; 70(2):325-30. PubMed ID: 21723015
[No Abstract] [Full Text] [Related]
19. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
